Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 5/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402628 | 0.85 | SLC6A3 (0.38) | SLC6A3HRH1CA2CA1CA9 | |
| SCHEMBL7396037 | 0.81 | HRH1 (0.52) | HRH1CA2CA1CA9CA12 | |
| SCHEMBL5394287 | 0.73 | CYP2C19 (0.37) | SLC6A3CA2CA1CA9CA12 | |
| SCHEMBL28854086 | 0.72 | TRPA1 (0.38) | SLC6A3HRH1HTR2ATAAR1CNR1 | |
| SCHEMBL11019672 | 0.72 | TRPA1 (0.38) | SLC6A3HRH1HTR2ATAAR1CNR1 | |
| SCHEMBL12497701 | 0.71 | GBA1 (0.47) | CA2CA1CA9CA5A | |
| SCHEMBL8533233 | 0.70 | GCK (0.47) | — | |
| SCHEMBL9203881 | 0.69 | CA2 (0.41) | HRH1CA2CA1CA9CA12 | |
| SCHEMBL1874636 | 0.69 | CA2 (0.35) | HRH1CA2CA1CA9CA12 | |
| SCHEMBL1876712 | 0.69 | SLC6A3 (0.40) | SLC6A3HRH1CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291643-B2 | Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof | WYETH (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070027201-A1 | Use of progesterone receptor modulators | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027126-A1 | E.g., N-[4-(5-cyano-1-methyl-1H-pyrrol-2-yl)phenyl]propane-1-sulfonamide and tert-butyl 2-cyano-5-{4-{(ethylsulfonyl)amino]phenyl}-1H-pyrrole-1-carboxylate; useful for contraception and hormone replacement therapy | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027201-A1 | Use of progesterone receptor modulators | GNRHR, PGR, FSHR | SLC6A3 1949/4885HRH1 588/4885CA2 2247/4885 |
| US-20070027126-A1 | E.g., N-[4-(5-cyano-1-methyl-1H-pyrrol-2-yl)phenyl]propane-1-sulfonamide and tert-butyl 2-cyano-5-{4-{(ethylsulfonyl)amino]phenyl}-1H-pyrrole-1-carboxylate; useful for contraception and hormone replacement therapy | GNRHR, PGR, PRLHR | SLC6A3 3487/4885HRH1 815/4885CA2 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.